The LMAT Paradox: Analysts Bullish But Forecast -11.82% Fall

Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with LeMaitre Vascular Inc ( LMAT). The average 12-month price target for LMAT — averaging the work of 5 analysts — reveals an average price target of $21.70/share. That's a whopping -11.82% below where LMAT has been trading recently at $24.61/share. With this kind of downside potential (should LMAT fall to that price target), one might expect to see a high concentration of "hold" or even "sell" ratings on the stock. Yet, take a look at the bullishness:

START SLIDESHOW:
10 ETFs With Most Upside To Analyst Targets »

Recent LMAT Analyst Ratings Breakdown
Current 1 Month Ago 2 Month Ago 3 Month Ago
Strong buy ratings: 4 5 5 5
Buy ratings: 0 0 0 0
Hold ratings: 1 1 0 0
Sell ratings: 0 0 0 0
Strong sell ratings: 0 0 0 0
Average rating: 1.4 1.33 1.0 1.0

The average rating presented in the last row of the table above is from 1 to 5, where 1 would be a consensus Strong Buy and 5 would be a consensus Strong Sell. In the middle, 3 would be a Hold. So anything below 3 leans toward Buy as the average analyst sentiment. The average rating of 1.4 for LMAT leans strongly towards the bullish end of the spectrum, yet the LMAT price target paints a different picture. Clearly, there is something more to the story here that is worth investigating for investors looking at LeMaitre Vascular Inc. Of course, the average price target is just that — a mathematical average, and is only one metric. There are analysts with higher targets than the average, including one looking for a price of $25.00. And then on the other side of the spectrum one analyst has a target as low as $18.00. The standard deviation is $2.588.

But the whole reason to look at the average in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes — much like with guessing the number of jelly beans in a jar, where the average guess tends to be very close. And so with LMAT trading so far above that average target price of $21.70/share, the -11.82% downside to that average target does seem to be a paradox against the bullish analyst ratings. Might analysts be behind the curve with their targets and upward adjustments are forthcoming? Or, is it time for some of these analysts to turn bearish and downgrade on valuation? One thing is for sure: this apparent paradox makes for a good "signal" to investors in LMAT to spend fresh time assessing the company and deciding whether analysts have it right with their sentiment, or have it right with their price target for LeMaitre Vascular Inc. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on LMAT — FREE.

If you liked this article you might like

5 Small-Caps That Could Be Big Performers

5 Small-Caps That Could Be Big Performers

4 Blue-Chip Health-Care Picks on Sale (and the Portfolio Is Up 163% Since 2006)

4 Blue-Chip Health-Care Picks on Sale (and the Portfolio Is Up 163% Since 2006)

Sales Are Flowing for Small-Cap Biotech

Sales Are Flowing for Small-Cap Biotech

Jim Cramer's 'Mad Money' Recap: Here's What's Important Next Week

Jim Cramer's 'Mad Money' Recap: Here's What's Important Next Week

Insider Trading Alert - HIL, PCRX And LMAT Traded By Insiders

Insider Trading Alert - HIL, PCRX And LMAT Traded By Insiders